PDGFRB signaling in the tumor microenvironment promotes epithelial-mesenchymal transition (EMT) and is inhibited by BRCA1, making it a significant therapeutic target, particularly in BRCA1-deficient TNBC (Bai et al., 2021). Here, PDGFRB is linked to neoplasm.